

---

**HOUSE BILL 2116**

---

**State of Washington**

**68th Legislature**

**2024 Regular Session**

**By** Representatives Thai, Slatter, Senn, Reed, Ormsby, Macri, Gregerson, Fosse, and Wylie

Prefiled 01/03/24. Read first time 01/08/24. Referred to Committee on Health Care & Wellness.

1 AN ACT Relating to expanding prescriptive authority for  
2 pharmacists; amending RCW 18.64.011 and 69.41.030; reenacting and  
3 amending RCW 69.50.101; adding a new section to chapter 18.64 RCW;  
4 and providing an effective date.

5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

6 **Sec. 1.** RCW 18.64.011 and 2021 c 78 s 1 are each amended to read  
7 as follows:

8 The definitions in this section apply throughout this chapter  
9 unless the context clearly requires otherwise.

10 (1) "Administer" means the direct application of a drug or  
11 device, whether by injection, inhalation, ingestion, or any other  
12 means, to the body of a patient or research subject.

13 (2) "Business licensing system" means the mechanism established  
14 by chapter 19.02 RCW by which business licenses, endorsed for  
15 individual state-issued licenses, are issued and renewed utilizing a  
16 business license application and a business license expiration date  
17 common to each renewable license endorsement.

18 (3) "Chart order" means a lawful order for a drug or device  
19 entered on the chart or medical record of an inpatient or resident of  
20 an institutional facility by a practitioner or his or her designated  
21 agent.

1 (4) "Closed door long-term care pharmacy" means a pharmacy that  
2 provides pharmaceutical care to a defined and exclusive group of  
3 patients who have access to the services of the pharmacy because they  
4 are treated by or have an affiliation with a long-term care facility  
5 or hospice program, and that is not a retailer of goods to the  
6 general public.

7 (5) "Commission" means the pharmacy quality assurance commission.

8 (6) "Compounding" means the act of combining two or more  
9 ingredients in the preparation of a prescription. Reconstitution and  
10 mixing of (a) sterile products according to federal food and drug  
11 administration-approved labeling does not constitute compounding if  
12 prepared pursuant to a prescription and administered immediately or  
13 in accordance with package labeling, and (b) nonsterile products  
14 according to federal food and drug administration-approved labeling  
15 does not constitute compounding if prepared pursuant to a  
16 prescription.

17 (7) "Controlled substance" means a drug or substance, or an  
18 immediate precursor of such drug or substance, so designated under or  
19 pursuant to the provisions of chapter 69.50 RCW.

20 (8) "Deliver" or "delivery" means the actual, constructive, or  
21 attempted transfer from one person to another of a drug or device,  
22 whether or not there is an agency relationship.

23 (9) "Department" means the department of health.

24 (10) "Device" means instruments, apparatus, and contrivances,  
25 including their components, parts, and accessories, intended (a) for  
26 use in the diagnosis, cure, mitigation, treatment, or prevention of  
27 disease in human beings or other animals, or (b) to affect the  
28 structure or any function of the body of human beings or other  
29 animals.

30 (11) "Dispense" means the interpretation of a prescription or  
31 order for a drug, biological, or device and, pursuant to that  
32 prescription or order, the proper selection, measuring, compounding,  
33 labeling, or packaging necessary to prepare that prescription or  
34 order for delivery.

35 (12) "Distribute" means the delivery of a drug or device other  
36 than by administering or dispensing.

37 (13) "Drug" and "devices" do not include surgical or dental  
38 instruments or laboratory materials, gas and oxygen, therapy  
39 equipment, X-ray apparatus or therapeutic equipment, their component  
40 parts or accessories, or equipment, instruments, apparatus, or

1 contrivances used to render such articles effective in medical,  
2 surgical, or dental treatment, or for use or consumption in or for  
3 mechanical, industrial, manufacturing, or scientific applications or  
4 purposes. "Drug" also does not include any article or mixture covered  
5 by the Washington pesticide control act (chapter 15.58 RCW), as  
6 enacted or hereafter amended, nor medicated feed intended for and  
7 used exclusively as a feed for animals other than human beings.

8 (14) "Drugs" means:

9 (a) Articles recognized in the official United States  
10 pharmacopoeia or the official homeopathic pharmacopoeia of the United  
11 States;

12 (b) Substances intended for use in the diagnosis, cure,  
13 mitigation, treatment, or prevention of disease in human beings or  
14 other animals;

15 (c) Substances (other than food) intended to affect the structure  
16 or any function of the body of human beings or other animals; or

17 (d) Substances intended for use as a component of any substances  
18 specified in (a), (b), or (c) of this subsection, but not including  
19 devices or their component parts or accessories.

20 (15) "Health care entity" means an organization that provides  
21 health care services in a setting that is not otherwise licensed by  
22 the state to acquire or possess legend drugs. Health care entity  
23 includes a freestanding outpatient surgery center, a residential  
24 treatment facility, and a freestanding cardiac care center. "Health  
25 care entity" does not include an individual practitioner's office or  
26 a multipractitioner clinic, regardless of ownership, unless the owner  
27 elects licensure as a health care entity. "Health care entity" also  
28 does not include an individual practitioner's office or  
29 multipractitioner clinic identified by a hospital on a pharmacy  
30 application or renewal pursuant to RCW 18.64.043.

31 (16) "Hospice program" means a hospice program certified or paid  
32 by medicare under Title XVIII of the federal social security act, or  
33 a hospice program licensed under chapter 70.127 RCW.

34 (17) "Institutional facility" means any organization whose  
35 primary purpose is to provide a physical environment for patients to  
36 obtain health care services including, but not limited to, services  
37 in a hospital, long-term care facility, hospice program, mental  
38 health facility, drug abuse treatment center, residential  
39 habilitation center, or a local, state, or federal correction  
40 facility.

1 (18) "Labeling" means the process of preparing and affixing a  
2 label to any drug or device container. The label must include all  
3 information required by current federal and state law and pharmacy  
4 rules.

5 (19) "Legend drugs" means any drugs which are required by any  
6 applicable federal or state law or regulation to be dispensed on  
7 prescription only or are restricted to use by practitioners only.

8 (20) "Long-term care facility" means a nursing home licensed  
9 under chapter 18.51 RCW, an assisted living facility licensed under  
10 chapter 18.20 RCW, or an adult family home licensed under chapter  
11 70.128 RCW.

12 (21) "Manufacture" means the production, preparation,  
13 propagation, compounding, or processing of a drug or other substance  
14 or device or the packaging or repackaging of such substance or  
15 device, or the labeling or relabeling of the commercial container of  
16 such substance or device, but does not include the activities of a  
17 practitioner who, as an incident to his or her administration or  
18 dispensing such substance or device in the course of his or her  
19 professional practice, personally prepares, compounds, packages, or  
20 labels such substance or device. "Manufacture" includes the  
21 distribution of a licensed pharmacy compounded drug product to other  
22 state licensed persons or commercial entities for subsequent resale  
23 or distribution, unless a specific product item has approval of the  
24 commission. The term does not include:

25 (a) The activities of a licensed pharmacy that compounds a  
26 product on or in anticipation of an order of a licensed practitioner  
27 for use in the course of their professional practice to administer to  
28 patients, either personally or under their direct supervision;

29 (b) The practice of a licensed pharmacy when repackaging  
30 commercially available medication in small, reasonable quantities for  
31 a practitioner legally authorized to prescribe the medication for  
32 office use only;

33 (c) The distribution of a drug product that has been compounded  
34 by a licensed pharmacy to other appropriately licensed entities under  
35 common ownership or control of the facility in which the compounding  
36 takes place; or

37 (d) The delivery of finished and appropriately labeled compounded  
38 products dispensed pursuant to a valid prescription to alternate  
39 delivery locations, other than the patient's residence, when

1 requested by the patient, or the prescriber to administer to the  
2 patient, or to another licensed pharmacy to dispense to the patient.

3 (22) "Manufacturer" means a person, corporation, or other entity  
4 engaged in the manufacture of drugs or devices.

5 (23) "Nonlegend" or "nonprescription" drugs means any drugs which  
6 may be lawfully sold without a prescription.

7 (24) "Person" means an individual, corporation, government,  
8 governmental subdivision or agency, business trust, estate, trust,  
9 partnership or association, or any other legal entity.

10 (25) "Pharmacist" means a person duly licensed by the commission  
11 to engage in the practice of pharmacy.

12 (26) "Pharmacy" means every place properly licensed by the  
13 commission where the practice of pharmacy is conducted.

14 (27) "Poison" does not include any article or mixture covered by  
15 the Washington pesticide control act (chapter 15.58 RCW), as enacted  
16 or hereafter amended.

17 (28) "Practice of pharmacy" includes the practice of and  
18 responsibility for: Interpreting prescription orders; the  
19 compounding, dispensing, labeling, administering, and distributing of  
20 drugs and devices; the monitoring of drug therapy and use; the  
21 initiating or modifying of drug therapy in accordance with written  
22 guidelines or protocols previously established and approved for his  
23 or her practice by a practitioner authorized to prescribe drugs; the  
24 prescribing and ordering of drugs and devices as authorized by the  
25 commission in rule; the participating in drug utilization reviews and  
26 drug product selection; the proper and safe storing and distributing  
27 of drugs and devices and maintenance of proper records thereof; the  
28 providing of information on legend drugs which may include, but is  
29 not limited to, the advising of therapeutic values, hazards, and the  
30 uses of drugs and devices.

31 (29) "Practitioner" means a physician, dentist, veterinarian,  
32 nurse, or other person duly authorized by law or rule in the state of  
33 Washington to prescribe drugs.

34 (30) "Prescription" means an order for drugs or devices issued by  
35 a practitioner duly authorized by law or rule in the state of  
36 Washington to prescribe drugs or devices in the course of his or her  
37 professional practice for a legitimate medical purpose.

38 (31) "Secretary" means the secretary of health or the secretary's  
39 designee.

1 (32) "Shared pharmacy services" means a system that allows a  
2 participating pharmacist or pharmacy pursuant to a request from  
3 another participating pharmacist or pharmacy to process or fill a  
4 prescription or drug order, which may include but is not necessarily  
5 limited to preparing, packaging, labeling, data entry, compounding  
6 for specific patients, dispensing, performing drug utilization  
7 reviews, conducting claims adjudication, obtaining refill  
8 authorizations, reviewing therapeutic interventions, or reviewing  
9 chart orders.

10 (33) "Wholesaler" means a corporation, individual, or other  
11 entity which buys drugs or devices for resale and distribution to  
12 corporations, individuals, or entities other than consumers.

13 NEW SECTION. **Sec. 2.** A new section is added to chapter 18.64  
14 RCW to read as follows:

15 By July 1, 2026, the commission shall adopt rules identifying  
16 specific drugs and devices, types or classes of drugs and devices, or  
17 both, that a pharmacist may prescribe in the absence of written  
18 guidelines or protocols previously established and approved for the  
19 pharmacist's practice by a practitioner authorized to prescribe  
20 drugs. The rules may also establish the types of patients or  
21 circumstances in which a pharmacist may or may not prescribe or order  
22 drugs or devices and any required education, training, or continuing  
23 education that must be completed prior to prescribing or ordering  
24 drugs or devices.

25 **Sec. 3.** RCW 69.41.030 and 2023 1st sp.s. c 1 s 4 are each  
26 amended to read as follows:

27 (1) It shall be unlawful for any person to sell or deliver any  
28 legend drug, or knowingly possess any legend drug, or knowingly use  
29 any legend drug in a public place, except upon the order or  
30 prescription of a physician under chapter 18.71 RCW, an osteopathic  
31 physician and surgeon under chapter 18.57 RCW, an optometrist  
32 licensed under chapter 18.53 RCW who is certified by the optometry  
33 board under RCW 18.53.010, a dentist under chapter 18.32 RCW, a  
34 podiatric physician and surgeon under chapter 18.22 RCW, a  
35 veterinarian under chapter 18.92 RCW, a commissioned medical or  
36 dental officer in the United States armed forces or public health  
37 service in the discharge of his or her official duties, a duly  
38 licensed physician or dentist employed by the veterans administration

1 in the discharge of his or her official duties, a registered nurse or  
2 advanced registered nurse practitioner under chapter 18.79 RCW when  
3 authorized by the (~~nursing care quality assurance commission~~) board  
4 of nursing, a pharmacist licensed under chapter 18.64 RCW to the  
5 extent permitted (~~by drug therapy guidelines or protocols~~  
6 ~~established under RCW 18.64.011 and authorized by the commission and~~  
7 ~~approved by a practitioner authorized to prescribe drugs~~) under  
8 chapter 18.64 RCW or when authorized by the commission, a physician  
9 assistant under chapter 18.71A RCW when authorized by the Washington  
10 medical commission, or any of the following professionals in any  
11 province of Canada that shares a common border with the state of  
12 Washington or in any state of the United States: A physician licensed  
13 to practice medicine and surgery or a physician licensed to practice  
14 osteopathic medicine and surgery, a dentist licensed to practice  
15 dentistry, a podiatric physician and surgeon licensed to practice  
16 podiatric medicine and surgery, a licensed advanced registered nurse  
17 practitioner, a licensed physician assistant, or a veterinarian  
18 licensed to practice veterinary medicine: PROVIDED, HOWEVER, That the  
19 above provisions shall not apply to sale, delivery, or possession by  
20 drug wholesalers or drug manufacturers, or their agents or employees,  
21 or to any practitioner acting within the scope of his or her license,  
22 or to a common or contract carrier or warehouse operator, or any  
23 employee thereof, whose possession of any legend drug is in the usual  
24 course of business or employment: PROVIDED FURTHER, That nothing in  
25 this chapter or chapter 18.64 RCW shall prevent a family planning  
26 clinic that is under contract with the health care authority from  
27 selling, delivering, possessing, and dispensing commercially  
28 prepackaged oral contraceptives prescribed by authorized, licensed  
29 health care practitioners: PROVIDED FURTHER, That nothing in this  
30 chapter prohibits possession or delivery of legend drugs by an  
31 authorized collector or other person participating in the operation  
32 of a drug take-back program authorized in chapter 69.48 RCW.

33 (2) (a) A violation of this section involving the sale, delivery,  
34 or possession with intent to sell or deliver is a class B felony  
35 punishable according to chapter 9A.20 RCW.

36 (b) A violation of this section involving knowing possession is a  
37 misdemeanor. The prosecutor is encouraged to divert such cases for  
38 assessment, treatment, or other services.

1 (c) A violation of this section involving knowing use in a public  
2 place is a misdemeanor. The prosecutor is encouraged to divert such  
3 cases for assessment, treatment, or other services.

4 (d) No person may be charged with both knowing possession and  
5 knowing use in a public place under this section relating to the same  
6 course of conduct.

7 (e) In lieu of jail booking and referral to the prosecutor for a  
8 violation of this section involving knowing possession, or knowing  
9 use in a public place, law enforcement is encouraged to offer a  
10 referral to assessment and services available under RCW 10.31.110 or  
11 other program or entity responsible for receiving referrals in lieu  
12 of legal system involvement, which may include, but are not limited  
13 to, arrest and jail alternative programs established under RCW  
14 36.28A.450, law enforcement assisted diversion programs established  
15 under RCW 71.24.589, and the recovery navigator program established  
16 under RCW 71.24.115.

17 (3) For the purposes of this section, "public place" has the same  
18 meaning as defined in RCW 66.04.010, but the exclusions in RCW  
19 66.04.011 do not apply.

20 (4) For the purposes of this section, "use any legend drug" means  
21 to introduce the drug into the human body by injection, inhalation,  
22 ingestion, or any other means.

23 **Sec. 4.** RCW 69.50.101 and 2023 c 365 s 2 and 2023 c 220 s 6 are  
24 each reenacted and amended to read as follows:

25 The definitions in this section apply throughout this chapter  
26 unless the context clearly requires otherwise.

27 ~~((a) — [(1)]))~~ (1) "Administer" means to apply a controlled  
28 substance, whether by injection, inhalation, ingestion, or any other  
29 means, directly to the body of a patient or research subject by:

30 ~~((1) — [(a)] — a))~~ (a) A practitioner authorized to prescribe (or,  
31 by the practitioner's authorized agent); or

32 ~~((2) — [(b)] — the))~~ (b) The patient or research subject at the  
33 direction and in the presence of the practitioner.

34 ~~((b) — [(2)]))~~ (2) "Agent" means an authorized person who acts on  
35 behalf of or at the direction of a manufacturer, distributor, or  
36 dispenser. It does not include a common or contract carrier, public  
37 warehouseperson, or employee of the carrier or warehouseperson.

38 ~~((c) — [(3)]))~~ (3) "Board" means the Washington state liquor and  
39 cannabis board.



1       (~~(d)~~—[~~(4)~~]) (4) "Cannabis" means all parts of the plant  
2 *Cannabis*, whether growing or not, with a THC concentration greater  
3 than 0.3 percent on a dry weight basis during the growing cycle  
4 through harvest and usable cannabis. "Cannabis" does not include hemp  
5 or industrial hemp as defined in RCW 15.140.020, or seeds used for  
6 licensed hemp production under chapter 15.140 RCW.

7       (~~(e)~~—[~~(5)~~]) (5) "Cannabis concentrates" means products  
8 consisting wholly or in part of the resin extracted from any part of  
9 the plant *Cannabis* and having a THC concentration greater than ten  
10 percent.

11       (~~(f)~~—[~~(6)~~]) (6) "Cannabis processor" means a person licensed by  
12 the board to process cannabis into cannabis concentrates, useable  
13 cannabis, and cannabis-infused products, package and label cannabis  
14 concentrates, useable cannabis, and cannabis-infused products for  
15 sale in retail outlets, and sell cannabis concentrates, useable  
16 cannabis, and cannabis-infused products at wholesale to cannabis  
17 retailers.

18       (~~(g)~~—[~~(7)~~]) (7) "Cannabis producer" means a person licensed by  
19 the board to produce and sell cannabis at wholesale to cannabis  
20 processors and other cannabis producers.

21       (~~(h)(1)~~—[~~(8)(a)~~]) (8)(a) "Cannabis products" means useable  
22 cannabis, cannabis concentrates, and cannabis-infused products as  
23 defined in this section, including any product intended to be  
24 consumed or absorbed inside the body by any means including  
25 inhalation, ingestion, or insertion, with any detectable amount of  
26 THC.

27       (~~(2)~~—[~~(b)~~]) (b) "Cannabis products" also means any product  
28 containing only THC content.

29       (~~(3)~~—[~~(e)~~]) (c) "Cannabis products" does not include cannabis  
30 health and beauty aids as defined in RCW 69.50.575 or products  
31 approved by the United States food and drug administration.

32       (~~(i)~~—[~~(9)~~]) (9) "Cannabis researcher" means a person licensed  
33 by the board to produce, process, and possess cannabis for the  
34 purposes of conducting research on cannabis and cannabis-derived drug  
35 products.

36       (~~(j)~~—[~~(10)~~]) (10) "Cannabis retailer" means a person licensed  
37 by the board to sell cannabis concentrates, useable cannabis, and  
38 cannabis-infused products in a retail outlet.

39       (~~(k)~~—[~~(11)~~]) (11) "Cannabis-infused products" means products  
40 that contain cannabis or cannabis extracts, are intended for human

1 use, are derived from cannabis as defined in subsection (~~(d)~~~~[(4)]~~)  
2 (4) of this section, and have a THC concentration no greater than ten  
3 percent. The term "cannabis-infused products" does not include either  
4 useable cannabis or cannabis concentrates.

5 (~~(1)~~~~[(12)]~~) (12) "CBD concentration" has the meaning provided  
6 in RCW 69.51A.010.

7 (~~(m)~~~~[(13)]~~) (13) "CBD product" means any product containing or  
8 consisting of cannabidiol.

9 (~~(n)~~~~[(14)]~~) (14) "Commission" means the pharmacy quality  
10 assurance commission.

11 (~~(o)~~~~[(15)]~~) (15) "Controlled substance" means a drug,  
12 substance, or immediate precursor included in Schedules I through V  
13 as set forth in federal or state laws, or federal or commission  
14 rules, but does not include hemp or industrial hemp as defined in RCW  
15 15.140.020.

16 (~~(p)~~~~(1)~~~~[(16)(a)]~~) (16)(a) "Controlled substance analog" means  
17 a substance the chemical structure of which is substantially similar  
18 to the chemical structure of a controlled substance in Schedule I or  
19 II and:

20 (i) that has a stimulant, depressant, or hallucinogenic effect on  
21 the central nervous system substantially similar to the stimulant,  
22 depressant, or hallucinogenic effect on the central nervous system of  
23 a controlled substance included in Schedule I or II; or

24 (ii) with respect to a particular individual, that the individual  
25 represents or intends to have a stimulant, depressant, or  
26 hallucinogenic effect on the central nervous system substantially  
27 similar to the stimulant, depressant, or hallucinogenic effect on the  
28 central nervous system of a controlled substance included in Schedule  
29 I or II.

30 (~~(2)~~~~[(b)]~~) (b) The term does not include:

31 (i) a controlled substance;

32 (ii) a substance for which there is an approved new drug  
33 application;

34 (iii) a substance with respect to which an exemption is in effect  
35 for investigational use by a particular person under Section 505 of  
36 the federal food, drug, and cosmetic act, 21 U.S.C. Sec. 355, or  
37 chapter 69.77 RCW to the extent conduct with respect to the substance  
38 is pursuant to the exemption; or

1 (iv) any substance to the extent not intended for human  
2 consumption before an exemption takes effect with respect to the  
3 substance.

4 (~~(q)~~—~~[(17)]~~) (17) "Deliver" or "delivery" means the actual or  
5 constructive transfer from one person to another of a substance,  
6 whether or not there is an agency relationship.

7 (~~(r)~~—~~[(18)]~~) (18) "Department" means the department of health.

8 (~~(s)~~—~~[(19)]~~) (19) "Designated provider" has the meaning  
9 provided in RCW 69.51A.010.

10 (~~(t)~~—~~[(20)]~~) (20) "Dispense" means the interpretation of a  
11 prescription or order for a controlled substance and, pursuant to  
12 that prescription or order, the proper selection, measuring,  
13 compounding, labeling, or packaging necessary to prepare that  
14 prescription or order for delivery.

15 (~~(u)~~—~~[(21)]~~) (21) "Dispenser" means a practitioner who  
16 dispenses.

17 (~~(v)~~—~~[(22)]~~) (22) "Distribute" means to deliver other than by  
18 administering or dispensing a controlled substance.

19 (~~(w)~~—~~[(23)]~~) (23) "Distributor" means a person who distributes.

20 (~~(x)~~—~~[(24)]~~) (24) "Drug" means (~~(1)~~—~~[(a)]~~) (a) a controlled  
21 substance recognized as a drug in the official United States  
22 pharmacopoeia/national formulary or the official homeopathic  
23 pharmacopoeia of the United States, or any supplement to them; (~~(2)~~—  
24 ~~[(b)]~~) (b) controlled substances intended for use in the diagnosis,  
25 cure, mitigation, treatment, or prevention of disease in individuals  
26 or animals; (~~(3)~~—~~[(c)]~~) (c) controlled substances (other than food)  
27 intended to affect the structure or any function of the body of  
28 individuals or animals; and (~~(4)~~—~~[(d)]~~) (d) controlled substances  
29 intended for use as a component of any article specified in (~~(1)~~—  
30 ~~(2), or (3)~~—~~[(a), (b), or (c)]~~) (a), (b), or (c) of this subsection.  
31 The term does not include devices or their components, parts, or  
32 accessories.

33 (~~(y)~~—~~[(25)]~~) (25) "Drug enforcement administration" means the  
34 drug enforcement administration in the United States Department of  
35 Justice, or its successor agency.

36 (~~(z)~~—~~[(26)]~~) (26) "Electronic communication of prescription  
37 information" means the transmission of a prescription or refill  
38 authorization for a drug of a practitioner using computer systems.  
39 The term does not include a prescription or refill authorization

1 verbally transmitted by telephone nor a facsimile manually signed by  
2 the practitioner.

3 ~~((aa) [(27)])~~ (27) "Immature plant or clone" means a plant or  
4 clone that has no flowers, is less than twelve inches in height, and  
5 is less than twelve inches in diameter.

6 ~~((bb) [(28)])~~ (28) "Immediate precursor" means a substance:

7 ~~((1) [(a)] that)~~ (a) That the commission has found to be and by  
8 rule designates as being the principal compound commonly used, or  
9 produced primarily for use, in the manufacture of a controlled  
10 substance;

11 ~~((2) [(b)] that)~~ (b) That is an immediate chemical intermediary  
12 used or likely to be used in the manufacture of a controlled  
13 substance; and

14 ~~((3) [(c)] the)~~ (c) The control of which is necessary to  
15 prevent, curtail, or limit the manufacture of the controlled  
16 substance.

17 ~~((ee) [(29)])~~ (29) "Isomer" means an optical isomer, but in  
18 subsection ~~((gg) (5) [(33) (e)])~~ (33) (e) of this section, RCW  
19 69.50.204 ~~((a) (12) and (34) [(1) (1) and (hh)])~~ (1) (1) and (hh),  
20 and 69.50.206 ~~((b) (4) [(2) (d)])~~ (2) (d), the term includes any  
21 geometrical isomer; in RCW 69.50.204 ~~((a) (8) and (42) [(1) (h) and~~  
22 ~~(pp)])~~ (1) (h) and (pp), and 69.50.210 ~~((e) [(3)])~~ (3) the term  
23 includes any positional isomer; and in RCW 69.50.204 ~~((a) (35)~~  
24 ~~[(1) (ii)])~~ (1) (ii), 69.50.204 ~~((e) [(3)])~~ (3), and 69.50.208 ~~((a)~~  
25 ~~[(1)])~~ (1) the term includes any positional or geometric isomer.

26 ~~((dd) [(30)])~~ (30) "Lot" means a definite quantity of cannabis,  
27 cannabis concentrates, useable cannabis, or cannabis-infused product  
28 identified by a lot number, every portion or package of which is  
29 uniform within recognized tolerances for the factors that appear in  
30 the labeling.

31 ~~((ee) [(31)])~~ (31) "Lot number" must identify the licensee by  
32 business or trade name and Washington state unified business  
33 identifier number, and the date of harvest or processing for each lot  
34 of cannabis, cannabis concentrates, useable cannabis, or cannabis-  
35 infused product.

36 ~~((ff) [(32)])~~ (32) "Manufacture" means the production,  
37 preparation, propagation, compounding, conversion, or processing of a  
38 controlled substance, either directly or indirectly or by extraction  
39 from substances of natural origin, or independently by means of  
40 chemical synthesis, or by a combination of extraction and chemical

1 synthesis, and includes any packaging or repackaging of the substance  
2 or labeling or relabeling of its container. The term does not include  
3 the preparation, compounding, packaging, repackaging, labeling, or  
4 relabeling of a controlled substance:

5 ~~((1) [(a)] by)~~ (a) By a practitioner as an incident to the  
6 practitioner's administering or dispensing of a controlled substance  
7 in the course of the practitioner's professional practice; or

8 ~~((2) [(b)] by)~~ (b) By a practitioner, or by the practitioner's  
9 authorized agent under the practitioner's supervision, for the  
10 purpose of, or as an incident to, research, teaching, or chemical  
11 analysis and not for sale.

12 ~~((gg) [(33)])~~ (33) "Narcotic drug" means any of the following,  
13 whether produced directly or indirectly by extraction from substances  
14 of vegetable origin, or independently by means of chemical synthesis,  
15 or by a combination of extraction and chemical synthesis:

16 ~~((1) [(a)])~~ (a) Opium, opium derivative, and any derivative of  
17 opium or opium derivative, including their salts, isomers, and salts  
18 of isomers, whenever the existence of the salts, isomers, and salts  
19 of isomers is possible within the specific chemical designation. The  
20 term does not include the isoquinoline alkaloids of opium.

21 ~~((2) [(b)])~~ (b) Synthetic opiate and any derivative of  
22 synthetic opiate, including their isomers, esters, ethers, salts, and  
23 salts of isomers, esters, and ethers, whenever the existence of the  
24 isomers, esters, ethers, and salts is possible within the specific  
25 chemical designation.

26 ~~((3) [(c)])~~ (c) Poppy straw and concentrate of poppy straw.

27 ~~((4) [(d)])~~ (d) Coca leaves, except coca leaves and extracts of  
28 coca leaves from which cocaine, ecgonine, and derivatives or ecgonine  
29 or their salts have been removed.

30 ~~((5) [(e)])~~ (e) Cocaine, or any salt, isomer, or salt of isomer  
31 thereof.

32 ~~((6) [(f)])~~ (f) Cocaine base.

33 ~~((7) [(g)])~~ (g) Ecgonine, or any derivative, salt, isomer, or  
34 salt of isomer thereof.

35 ~~((8) [(h)])~~ (h) Any compound, mixture, or preparation  
36 containing any quantity of any substance referred to in ~~((1) [(a)])~~  
37 (a) through ~~((7) [(g)])~~ (g) of this subsection.

38 ~~((hh) [(34)])~~ (34) "Opiate" means any substance having an  
39 addiction-forming or addiction-sustaining liability similar to  
40 morphine or being capable of conversion into a drug having addiction-

1 forming or addiction-sustaining liability. The term includes opium,  
2 substances derived from opium (opium derivatives), and synthetic  
3 opiates. The term does not include, unless specifically designated as  
4 controlled under RCW 69.50.201, the dextrorotatory isomer of 3-  
5 methoxy-n-methylmorphinan and its salts (dextromethorphan). The term  
6 includes the racemic and levorotatory forms of dextromethorphan.

7 ~~((ii) [(35)])~~ (35) "Opium poppy" means the plant of the species  
8 *Papaver somniferum* L., except its seeds.

9 ~~((jj) [(36)])~~ (36) "Package" means a container that has a  
10 single unit or group of units.

11 ~~((kk) [(37)])~~ (37) "Person" means individual, corporation,  
12 business trust, estate, trust, partnership, association, joint  
13 venture, government, governmental subdivision or agency, or any other  
14 legal or commercial entity.

15 ~~((ll) [(38)])~~ (38) "Plant" has the meaning provided in RCW  
16 69.51A.010.

17 ~~((mm) [(39)])~~ (39) "Poppy straw" means all parts, except the  
18 seeds, of the opium poppy, after mowing.

19 ~~((nn) [(40)])~~ (40) "Practitioner" means:

20 ~~((1) [(a)])~~ (a) A physician under chapter 18.71 RCW; a  
21 physician assistant under chapter 18.71A RCW; an osteopathic  
22 physician and surgeon under chapter 18.57 RCW; an optometrist  
23 licensed under chapter 18.53 RCW who is certified by the optometry  
24 board under RCW 18.53.010 subject to any limitations in RCW  
25 18.53.010; a dentist under chapter 18.32 RCW; a podiatric physician  
26 and surgeon under chapter 18.22 RCW; a veterinarian under chapter  
27 18.92 RCW; a registered nurse, advanced registered nurse  
28 practitioner, or licensed practical nurse under chapter 18.79 RCW; a  
29 naturopathic physician under chapter 18.36A RCW who is licensed under  
30 RCW 18.36A.030 subject to any limitations in RCW 18.36A.040; a  
31 pharmacist under chapter 18.64 RCW subject to any limitations in RCW  
32 18.64.011, section 2 of this act, and rules adopted by the  
33 commission; or a scientific investigator under this chapter,  
34 licensed, registered or otherwise permitted insofar as is consistent  
35 with those licensing laws to distribute, dispense, conduct research  
36 with respect to or administer a controlled substance in the course of  
37 their professional practice or research in this state.

38 ~~((2) [(b)])~~ (b) A pharmacy, hospital or other institution  
39 licensed, registered, or otherwise permitted to distribute, dispense,  
40 conduct research with respect to or to administer a controlled

1 substance in the course of professional practice or research in this  
2 state.

3 ~~((3) [(e)])~~ (c) A physician licensed to practice medicine and  
4 surgery, a physician licensed to practice osteopathic medicine and  
5 surgery, a dentist licensed to practice dentistry, a podiatric  
6 physician and surgeon licensed to practice podiatric medicine and  
7 surgery, a licensed physician assistant or a licensed osteopathic  
8 physician assistant specifically approved to prescribe controlled  
9 substances by his or her state's medical commission or equivalent and  
10 his or her supervising physician, an advanced registered nurse  
11 practitioner licensed to prescribe controlled substances, or a  
12 veterinarian licensed to practice veterinary medicine in any state of  
13 the United States.

14 ~~((oo) [(41)])~~ (41) "Prescription" means an order for controlled  
15 substances issued by a practitioner duly authorized by law or rule in  
16 the state of Washington to prescribe controlled substances within the  
17 scope of his or her professional practice for a legitimate medical  
18 purpose.

19 ~~((pp) [(42)])~~ (42) "Production" includes the manufacturing,  
20 planting, cultivating, growing, or harvesting of a controlled  
21 substance.

22 ~~((qq) [(43)])~~ (43) "Qualifying patient" has the meaning  
23 provided in RCW 69.51A.010.

24 ~~((rr) [(44)])~~ (44) "Recognition card" has the meaning provided  
25 in RCW 69.51A.010.

26 ~~((ss) [(45)])~~ (45) "Retail outlet" means a location licensed by  
27 the board for the retail sale of cannabis concentrates, useable  
28 cannabis, and cannabis-infused products.

29 ~~((tt) [(46)])~~ (46) "Secretary" means the secretary of health or  
30 the secretary's designee.

31 ~~((uu) [(47)])~~ (47) "Social equity plan" means a plan that  
32 addresses at least some of the elements outlined in this subsection  
33 ~~((uu) [(47)])~~ (47), along with any additional plan components or  
34 requirements approved by the board following consultation with the  
35 task force created in RCW 69.50.336. The plan may include:

36 ~~((1) [(a)])~~ (a) A statement that indicates how the cannabis  
37 licensee will work to promote social equity goals in their community;

38 ~~((2) [(b)])~~ (b) A description of how the cannabis licensee will  
39 meet social equity goals as defined in RCW 69.50.335;

1       (~~(3)~~—~~(e)~~)) (c) The composition of the workforce the licensee  
2 has employed or intends to hire; and

3       (~~(4)~~—~~(d)~~)) (d) Business plans involving partnerships or  
4 assistance to organizations or residents with connections to  
5 populations with a history of high rates of enforcement of cannabis  
6 prohibition.

7       (~~(vv)~~—~~(48)~~)) (48) "State," unless the context otherwise  
8 requires, means a state of the United States, the District of  
9 Columbia, the Commonwealth of Puerto Rico, or a territory or insular  
10 possession subject to the jurisdiction of the United States.

11       (~~(ww)~~—~~(49)~~)) (49) "THC concentration" means percent of  
12 tetrahydrocannabinol content of any part of the plant *Cannabis*, or  
13 per volume or weight of cannabis product, or the combined percent of  
14 tetrahydrocannabinol and tetrahydrocannabinolic acid in any part of  
15 the plant *Cannabis* regardless of moisture content.

16       (~~(xx)~~—~~(50)~~)) (50) "Ultimate user" means an individual who  
17 lawfully possesses a controlled substance for the individual's own  
18 use or for the use of a member of the individual's household or for  
19 administering to an animal owned by the individual or by a member of  
20 the individual's household.

21       (~~(yy)~~—~~(51)~~)) (51) "Unit" means an individual consumable item  
22 within a package of one or more consumable items in solid, liquid,  
23 gas, or any form intended for human consumption.

24       (~~(zz)~~—~~(52)~~)) (52) "Useable cannabis" means dried cannabis  
25 flowers. The term "useable cannabis" does not include either  
26 cannabis-infused products or cannabis concentrates.

27       (~~(aaa)~~—~~(53)~~)) (53) "Youth access" means the level of interest  
28 persons under the age of twenty-one may have in a vapor product, as  
29 well as the degree to which the product is available or appealing to  
30 such persons, and the likelihood of initiation, use, or addiction by  
31 adolescents and young adults.

32       NEW SECTION.   **Sec. 5.** Sections 1, 3, and 4 of this act take  
33 effect July 1, 2026.

--- END ---